Viraj Mehta trusts the toughness and bounce of a company that has seen many trials
Nocil has a significant market share in the domestic and global rubber chemicals industry, and is ready to ride the China-plus-one wave
Viraj Mehta - May 04, 2021
IT stocks are in favour for the same reason that consumer staples seem to be out of favour
Growth predictability arising out of adoption of digital technology has pushed up valuation of software companies
Shruti Venkatesh - September 05, 2020
What does Rakesh Jhunjhunwala see in Jubilant Life Sciences?
Within a year, the investing legend has doubled down on his latest pharma bet
Himanshu Kakkar - May 23, 2020
Viraj Mehta believes this stock is the perfect safe haven
With steady cash flow, robust business model and prudent risk management, Manappuram Finance’s future looks golden
April 09, 2020
What next for IndusInd Bank?
Grappling with bad loans, weak loan growth and leadership uncertainty, its valuation is under pressure
Prathamesh Mulye - January 15, 2020
HCL Tech’s trump card
The company makes do with a lower multiple because of weak core revenue, but analysts are betting on the IBM products acquisition to turn things around
Prathamesh Mulye - January 08, 2020
Speedway to profit
HG Infra Engineering has catapulted itself into a high growth, high-margin bracket with smart asset-building and bidding
Himanshu Kakkar - May 16, 2019
Viraj Mehta
Alkyl Amines Chemicals operates in a niche business, but has all the strappings of a multibagger, feels the head (PMS) of Equirus Securities
April 15, 2019
Is it an opportune time to invest in pharma stocks?
Over the past three years, the NSE Pharma Index has fallen 30% even as the benchmark Nifty rose 18%
June 20, 2018
Viraj Mehta
Equirus Securities's head (PMS) believes Thangamayil Jewellery will gain sheen in a post-GST era
December 14, 2017